Trial Profile

Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Escitalopram (Primary) ; Vortioxetine (Primary)
Indications Major depressive disorder
Focus Therapeutic Use

Most Recent Events

15 Sep 2020 Results (n=125) presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
15 Sep 2020 Results (n=73) assessing vortioxetine treatment elevates serum BDNF levels in MDD patients along with the improvement of cognitive and emotional characteristics, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
08 Jan 2019 Planned End Date changed from 1 Sep 2018 to 1 Apr 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com